(Total Views: 700)
Posted On: 04/05/2022 11:56:17 AM
Post# of 148899
A preprint was published last week showing Remdesivir did not improve outcomes in hospitalized patients. Here is a summary of the study from another publication.
A new preprint has shown that Gilead’s remdesivir did not show any improvement compared to placebo in treating hospitalized Covid-19 patients.
The preprint, published Thursday and yet to be peer-reviewed, said that remdesivir plus standard of care did not result in such patients significantly improving after two weeks. The study observed hospitalized patients in Europe from March 2020 to January 2021.
Investigators noted the study was randomized and open-label. The reported p-value for the difference between treatment groups was p=0.93.
“Remdesivir use for the treatment of hospitalised patients with COVID-19 was not associated with clinical improvement at day 15,” the study summed up bluntly.
The study comes as the FDA recently green-lighted remdesivir, marketed as Veklury, for outpatient treatment of patients older than 12 — an expansion of its previous label for only those older than 12 and hospitalized.
After becoming the first treatment to win an EUA to treat Covid-19, Veklury has proved a big revenue generator for Gilead. In 2021, the drug pulled in $5.6 billion in sales.
No surprises in the study, but when thinking about potential market value of CYDY, note the $5.6B in sales last year. Link below is to the preprint. I noticed that 14 of the study authors received personal fees from Gilead "outside the submitted work" and/or "non-financial support" from Gilead.
https://www.medrxiv.org/content/10.1101/2022....22273206v1
A new preprint has shown that Gilead’s remdesivir did not show any improvement compared to placebo in treating hospitalized Covid-19 patients.
The preprint, published Thursday and yet to be peer-reviewed, said that remdesivir plus standard of care did not result in such patients significantly improving after two weeks. The study observed hospitalized patients in Europe from March 2020 to January 2021.
Investigators noted the study was randomized and open-label. The reported p-value for the difference between treatment groups was p=0.93.
“Remdesivir use for the treatment of hospitalised patients with COVID-19 was not associated with clinical improvement at day 15,” the study summed up bluntly.
The study comes as the FDA recently green-lighted remdesivir, marketed as Veklury, for outpatient treatment of patients older than 12 — an expansion of its previous label for only those older than 12 and hospitalized.
After becoming the first treatment to win an EUA to treat Covid-19, Veklury has proved a big revenue generator for Gilead. In 2021, the drug pulled in $5.6 billion in sales.
No surprises in the study, but when thinking about potential market value of CYDY, note the $5.6B in sales last year. Link below is to the preprint. I noticed that 14 of the study authors received personal fees from Gilead "outside the submitted work" and/or "non-financial support" from Gilead.
https://www.medrxiv.org/content/10.1101/2022....22273206v1
(9)
(0)Scroll down for more posts ▼
